Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers
News
Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a ... Read more